Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study

Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study

We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in th...

Full description

Bibliographic Details
Main Authors: Seiichiro Katagiri, Daigo Akahane, Shunsuke Otsuki, Arisa Suto, Akiko Yamada, Tamiko Suguro, Michiyo Asano, Seiichiro Yoshizawa, Yuko Tanaka, Nahoko Furuya, Hiroaki Fujimoto, Seiichi Okabe, Moritaka Gotoh, Yoshikazu Ito, Akihiko Gotoh
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Vaccines
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitors
BNT162b2 vaccine
anti-spike IgG
Online Access:https://www.mdpi.com/2076-393X/10/9/1404

Internet

https://www.mdpi.com/2076-393X/10/9/1404

Similar Items